On August 27, 2025 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025 (Press release, Alpha Tau Medical, AUG 27, 2025, View Source [SID1234655506]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Alpha DaRT platform is a novel approach using localized alpha particle radiotherapy with the goal of destroying solid tumors while sparing surrounding healthy tissue. With broad potential applicability for local tumor control, together with signs of compelling immuno-stimulatory activity, the platform technology is being explored for utilization alone or synergistically with other cancer treatment modalities. Key milestones and pivotal data from multiple clinical trials in different indications are expected in 2025 and 2026.
Event: Citi 2025 Biopharma Back to School Summit
Format: 1×1 Meetings
Date: September 2-3, 2025
Location: Boston, MA
Event: H.C. Wainwright 27th Annual Global Investment Conference
Format: Company Presentation and 1×1 Meetings
Date: September 9, 2025
Time 3:00 – 3:30pm
Location: New York, NY
Event: Oppenheimer’s Third Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Format: 1×1 Meetings
Date: September 11, 2025
Location: New York, NY
Event: RTH & Co / Redburn Atlantic – Radiopharma Landscape Conference
Format: 1×1 Meetings
Date: September 26, 2025
Location: New York, NY
Event: Lytham Partners Fall 2025 Investor Conference
Format: 1×1 Meetings
Date: September 30, 2025
Location: Virtual
Mr. Levy will be available for 1×1 investor meetings at all conferences. Please reach out to your representatives at the respective conference organizers to schedule.
About Alpha DaRT
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.